NASDAQ:SESN - Sesen Bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.50
  • Forecasted Upside: 72.41 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.35
▼ -0.15 (-3.33%)
1 month | 3 months | 12 months
Get New Sesen Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SESN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SESN

Average Price Target: $7.50
▲ +72.41% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Sesen Bio in the last 3 months. The average price target is $7.50, with a high forecast of $8.00 and a low forecast of $7.00. The average price target represents a 72.41% upside from the last price of $4.35.

Buy

The current consensus among 2 investment analysts is to buy stock in Sesen Bio. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/16/2021Canaccord GenuityReiterated RatingBuy$7.00High
2/17/2021HC WainwrightBoost Price TargetBuy$2.25 ➝ $8.00Low
2/16/2021Canaccord GenuityBoost Price TargetHold ➝ Buy$5.00 ➝ $7.00Low
1/25/2021Canaccord GenuityReiterated RatingBuyHigh
10/7/2020Canaccord GenuityReiterated RatingBuy$5.00Low
8/4/2020Canaccord GenuityReiterated RatingBuy$5.00Low
5/12/2020Canaccord GenuityReiterated RatingBuy$5.00Low
11/13/2019HC WainwrightReiterated RatingBuy$2.25Low
8/9/2019LaidlawDowngradeBuy ➝ HoldHigh
6/11/2019HC WainwrightUpgradeNeutral ➝ Buy$1.00 ➝ $3.00Medium
5/14/2019HC WainwrightReiterated RatingHold$1.00Medium
3/5/2019HC WainwrightSet Price TargetHold$1.00Medium
2/6/2019Jefferies Financial GroupReiterated RatingBuy$3.00Low
1/4/2019HC WainwrightDowngradeBuy ➝ Neutral$1.00High
11/28/2018HC WainwrightSet Price TargetBuy$3.00Low
11/12/2018HC WainwrightSet Price TargetBuy$3.00Medium
7/23/2018Jefferies Financial GroupInitiated CoverageBuy$4.00High
7/9/2018Canaccord GenuityInitiated CoverageBuyMedium
5/22/2018HC WainwrightBoost Price TargetBuy ➝ In-Line$3.50High
(Data available from 6/21/2016 forward)
Sesen Bio logo
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $4.35
Low: $4.20
High: $4.65

50 Day Range

MA: $3.08
Low: $2.18
High: $4.50

52 Week Range

Now: $4.35
Low: $0.66
High: $4.68

Volume

25,431,400 shs

Average Volume

6,522,046 shs

Market Capitalization

$753.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Frequently Asked Questions

What sell-side analysts currently cover shares of Sesen Bio?

The following Wall Street analysts have issued research reports on Sesen Bio in the last twelve months: Canaccord Genuity, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for SESN.

What is the current price target for Sesen Bio?

2 Wall Street analysts have set twelve-month price targets for Sesen Bio in the last year. Their average twelve-month price target is $7.50, suggesting a possible upside of 72.4%. HC Wainwright has the highest price target set, predicting SESN will reach $8.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $7.00 for Sesen Bio in the next year.
View the latest price targets for SESN.

What is the current consensus analyst rating for Sesen Bio?

Sesen Bio currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SESN will outperform the market and that investors should add to their positions of Sesen Bio.
View the latest ratings for SESN.

What other companies compete with Sesen Bio?

How do I contact Sesen Bio's investor relations team?

Sesen Bio's physical mailing address is 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142. The company's listed phone number is 617-444-8550 and its investor relations email address is [email protected] The official website for Sesen Bio is www.sesenbio.com.